Mechanisms of Chronic Pathobiology in Allografts

同种异体移植物的慢性病理生物学机制

基本信息

  • 批准号:
    6946494
  • 负责人:
  • 金额:
    $ 129.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-09-30 至 2007-08-31
  • 项目状态:
    已结题

项目摘要

Chronic allograft rejection is an immune-promoted pathologic remodeling of allograft tissues which is severe enough to compromise physiologic function. An understanding of this remodeling process requires an understanding of agents that connect alloimmunity with histogenesis. One important connecting agent if TGFbeta which alters leukocyte behavior and stimulates fibrotic tissue remodeling. We believe that chronic TGFbeta production represents a basic pathologic stimulus for the many different histologic features of chronic rejection that appear in different tissues. We have assembled a team of PIs with diverse scientific expertise to study the alloimmune processes that generate TGFbeta, and the mechanisms by which TGFbeta promotes pathogenesis in allografts. Project 1 will use intact animal models to test the hypothesis that alloantibodies stimulate fibrotic remodeling events through macrophages, causing them to produce TGFbeta through chronic Fcgamma and apoptosis receptor engagement. Project 2 will use in vitro studies with human macrophages to investigate the intercellular signaling systems employed when alloantibodies stimulate macrophages via FcgammaR, allowing them to avoid apoptosis and to produce pro- inflammatory cytokines, including TGFbeta. Project 3 will study human and murine allografts to test the hypothesis that transcription reprogramming of stromal cells by the TGFbeta-inducible gene regulator MSY1 drives many of the pathologic developments observed during chronic allograft rejection. Thus, the PIs will attach this problem at the systemic, cellular and genetic levels. They will also provide each other with unique insights and valuable research tools. These projects will be assisted by two core facilities: an Administrative/Statistical Core (Core A) and a Histopathology/Morphometrics Core (Core B). Core A will provider organizational support, secretarial services, budget accounting, and statistical services. Core B will provide the expertise of a veteran transplant pathologist, as well as the technical capabilities for tissue sectioning, histologic and immunohistologic tissue staining, and microscopic and morphometric analyses of stained tissues. In general, this Program Project reflects the efforts of an enthusiastic and highly interactive team of investigators. They have taken advantage of their diverse scientific interests to develop several unique hypotheses and compelling preliminary data regarding the basic biology of chronic allograft rejection. They are well organized, and have strong, active support from their institution.
慢性同种异体移植排斥反应是一种免疫促进的病理性移植组织重建,严重时可损害移植组织的生理功能。要了解这种重塑过程,需要了解将同种免疫与组织发生联系起来的试剂。一种重要的连接剂是TGF β,它改变白细胞行为并刺激纤维化组织重塑。我们认为,慢性TGF β产生代表了出现在不同组织中的慢性排斥反应的许多不同组织学特征的基本病理刺激。我们已经组建了一个具有不同科学专业知识的PI团队,以研究产生TGF β的同种免疫过程,以及TGF β促进同种异体移植物发病机制的机制。项目1将使用完整的动物模型来检验同种抗体通过巨噬细胞刺激纤维化重塑事件,导致它们通过慢性Fc γ和凋亡受体结合产生TGF β的假设。项目2将使用人巨噬细胞的体外研究来研究当同种抗体通过Fc γ R刺激巨噬细胞时所采用的细胞间信号传导系统,从而使它们避免细胞凋亡并产生促炎细胞因子,包括TGF β。项目3将研究人类和小鼠的同种异体移植物,以检验以下假设:TGF β诱导的基因调节因子MSY 1对基质细胞的转录重编程驱动了慢性同种异体移植物排斥反应期间观察到的许多病理发展。因此,PI将在系统,细胞和遗传水平上解决这个问题。他们还将为彼此提供独特的见解和宝贵的研究工具。这些项目将得到两个核心设施的协助:行政/统计核心(核心A)和历史学/形态计量学核心(核心B)。核心A将提供组织支助、秘书服务、预算会计和统计服务。核心B将提供经验丰富的移植病理学家的专业知识,以及组织切片、组织学和免疫组织学组织染色以及染色组织的显微镜和形态学分析的技术能力。总的来说,这个计划项目反映了一个热情和高度互动的调查团队的努力。他们利用他们不同的科学兴趣,发展了几个独特的假设和令人信服的初步数据有关的慢性同种异体移植排斥反应的基础生物学。他们组织良好,并得到其机构的有力、积极支持。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARTHUR ROGER STRAUCH其他文献

ARTHUR ROGER STRAUCH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARTHUR ROGER STRAUCH', 18)}}的其他基金

Peri-arteriolar Myofibroblast Differentiation in the Pathobiology of IPAH
IPAH 病理学中小动脉周围肌成纤维细胞的分化
  • 批准号:
    8335478
  • 财政年份:
    2011
  • 资助金额:
    $ 129.43万
  • 项目类别:
Peri-arteriolar Myofibroblast Differentiation in the Pathobiology of IPAH
IPAH 病理学中小动脉周围肌成纤维细胞的分化
  • 批准号:
    8211724
  • 财政年份:
    2011
  • 资助金额:
    $ 129.43万
  • 项目类别:
Targeting myofibroblast activation in chronic fibrotic disease
靶向慢性纤维化疾病中的肌成纤维细胞激活
  • 批准号:
    7824428
  • 财政年份:
    2009
  • 资助金额:
    $ 129.43万
  • 项目类别:
Targeting myofibroblast activation in chronic fibrotic disease
靶向慢性纤维化疾病中的肌成纤维细胞激活
  • 批准号:
    7741692
  • 财政年份:
    2007
  • 资助金额:
    $ 129.43万
  • 项目类别:
Targeting myofibroblast activation in chronic fibrotic disease
靶向慢性纤维化疾病中的肌成纤维细胞激活
  • 批准号:
    7387757
  • 财政年份:
    2007
  • 资助金额:
    $ 129.43万
  • 项目类别:
Targeting myofibroblast activation in chronic fibrotic disease
靶向慢性纤维化疾病中的肌成纤维细胞激活
  • 批准号:
    7536051
  • 财政年份:
    2007
  • 资助金额:
    $ 129.43万
  • 项目类别:
Myofibroblasts and fibrosis after cardiac transplant
心脏移植后的肌成纤维细胞和纤维化
  • 批准号:
    6659328
  • 财政年份:
    2002
  • 资助金额:
    $ 129.43万
  • 项目类别:
TRANSCRIPTIONAL BASIS OF CARDIAC ALLOGRAFT REMODELING
心脏同种异体移植重构的转录基础
  • 批准号:
    6184995
  • 财政年份:
    1999
  • 资助金额:
    $ 129.43万
  • 项目类别:
TRANSCRIPTIONAL BASIS OF CARDIAC ALLOGRAFT REMODELING
心脏同种异体移植重构的转录基础
  • 批准号:
    6537441
  • 财政年份:
    1999
  • 资助金额:
    $ 129.43万
  • 项目类别:
TRANSCRIPTIONAL BASIS OF CARDIAC ALLOGRAFT REMODELING
心脏同种异体移植重构的转录基础
  • 批准号:
    6638499
  • 财政年份:
    1999
  • 资助金额:
    $ 129.43万
  • 项目类别:

相似海外基金

Disruptive technologies for rapid detection of renal transplant rejection
快速检测肾移植排斥反应的颠覆性技术
  • 批准号:
    EP/Y036328/1
  • 财政年份:
    2024
  • 资助金额:
    $ 129.43万
  • 项目类别:
    Research Grant
Targeting the transcriptional co-activators YAP and TAZ with statins to prevent solid organ transplant rejection by HLA donor specific antibodies
用他汀类药物靶向转录共激活剂 YAP 和 TAZ,以防止 HLA 供体特异性抗体导致实体器官移植排斥
  • 批准号:
    10734277
  • 财政年份:
    2023
  • 资助金额:
    $ 129.43万
  • 项目类别:
Localized immuno-cloaking organ engineering approach to prevent transplant rejection without immunosuppressants
局部免疫隐匿器官工程方法无需免疫抑制剂即可预防移植排斥
  • 批准号:
    468759
  • 财政年份:
    2022
  • 资助金额:
    $ 129.43万
  • 项目类别:
    Operating Grants
A Nanopathology Platform for Prediction and Early Detection of Disease in Kidney Transplant Rejection
用于预测和早期检测肾移植排斥疾病的纳米病理学平台
  • 批准号:
    MR/W031426/1
  • 财政年份:
    2022
  • 资助金额:
    $ 129.43万
  • 项目类别:
    Research Grant
Single Cell Analysis of Alloreactive CD8+ T Cells in Kidney Transplant Rejection
肾移植排斥反应中同种异体 CD8 T 细胞的单细胞分析
  • 批准号:
    10607410
  • 财政年份:
    2022
  • 资助金额:
    $ 129.43万
  • 项目类别:
Characterizing Emerging Humanized Immune Mouse Models for the study of transplant rejection and infectious disease pathology (Epstein Barr Virus)
表征新兴人源化免疫小鼠模型,用于研究移植排斥和传染病病理学(EB 病毒)
  • 批准号:
    10919145
  • 财政年份:
    2021
  • 资助金额:
    $ 129.43万
  • 项目类别:
The utility of chimeric antigen receptor-engineered regulatory T cell immunotherapy to prevent islet transplant rejection in type 1 diabetic mice
嵌合抗原受体工程调节性 T 细胞免疫疗法预防 1 型糖尿病小鼠胰岛移植排斥反应的应用
  • 批准号:
    458994
  • 财政年份:
    2021
  • 资助金额:
    $ 129.43万
  • 项目类别:
    Studentship Programs
IRI, innate immunity and transplant rejection
IRI、先天免疫和移植排斥
  • 批准号:
    10576902
  • 财政年份:
    2021
  • 资助金额:
    $ 129.43万
  • 项目类别:
Characterizing Emerging Humanized Immune Mouse Models for the study of transplant rejection and infectious disease pathology (Epstein Barr Virus)
表征新兴人源化免疫小鼠模型,用于研究移植排斥和传染病病理学(EB 病毒)
  • 批准号:
    10493887
  • 财政年份:
    2021
  • 资助金额:
    $ 129.43万
  • 项目类别:
Development of a novel acoustofluidic device for targeted antibody removal in pediatric organ transplant rejection
开发一种新型声流控装置,用于去除儿科器官移植排斥反应中的靶向抗体
  • 批准号:
    10372229
  • 财政年份:
    2021
  • 资助金额:
    $ 129.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了